Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion
Eduardo Ferreira de Castro-Neto, Rafael Henrique Da Cunha, Dartiu Xavier Da Silveira, Maurı́cio Yonamine, Telma Luciana Furtado Gouveia, Ésper A. Cavalheiro, Débora Amado, Maria Da Graça Naffah‐mazzacoratti
World Journal of Biological Chemistry January 1, 2013 DOI: 10.4331/wjbc.v4.i4.141 via OpenAlex
Summary
AI-generated from the abstractIn rats given ayahuasca by gavage at doses of 250, 500, or 800 mg/kg, the hippocampus showed increased levels of the inhibitory neurotransmitter GABA at all doses, while the amygdala showed decreased levels of the inhibitory amino acids glycine and GABA at the two higher doses. The amygdala also exhibited an increased utilization rate of the monoamines noradrenaline, dopamine, and serotonin at all three doses. These results suggest that ayahuasca ingestion increases inhibitory amino acid release in the hippocampus and increases monoamine turnover in the amygdala.
Study at a glance
| Characteristics | Controlled experiment Peer reviewed |
|---|---|
| Population | Naive rats |
| Intervention | Ayahuasca infusion |
| Dose | 250, 500 and 800 mg/kg |
| Duration | 40 min after ingestion |
| Topics | Ayahuasca |
| Keywords | Monoamine neurotransmitter Ingestion Hippocampus Amygdala |
| Citations | 51 |
| Key finding | Ayahuasca ingestion increased GABA levels in the hippocampus and decreased glycine and GABA levels in the amygdala, while increasing monoamine utilization rates in the amygdala. |
Abstract
AIM: To evaluate changes in neurotransmission induced by a psychoactive beverage ayahuasca in the hippocampus and amygdala of naive rats. METHODS: The level of monoamines, their main metabolites and amino acid neurotransmitters concentrations were quantified using high performance liquid chromatography (HPLC). Four groups of rats were employed: saline-treated and rats receiving 250, 500 and 800 mg/kg of ayahuasca infusion (gavage). Animals were killed 40 min after drug ingestion and the structures stored at -80 °C until HPLC assay. The data from all groups were compared using Analysis of variance and Scheffé as post test and P < 0.05 was accepted as significant. RESULTS: The results showed decreased concentrations of glycine (GLY) (0.13 ± 0.03 vs 0.29 ± 0.07, P < 0.001) and γ-aminobutyric acid (GABA) (1.07 ± 0.14 vs 1.73 ± 0.25, P < 0.001) in the amygdala of rats that received 500 of ayahuasca. Animals that ingested 800 mg/kg of ayahuasca also showed a reduction of GLY level (0.11 ± 0.01 vs 0.29 ± 0.07, P < 0.001) and GABA (0.98 ± 0.06 vs 1.73 ± 0.25, P < 0.001). In the hippocampus, increased GABA levels were found in rats that received all ayahuasca doses: 250 mg/kg (1.29 ± 0.19 vs 0.84 ± 0.21, P < 0.05); 500 mg/kg (2.23 ± 038 vs 084 ± 0.21, P < 0.05) and 800 mg/kg (1.98 ± 0.92 vs 0.84 ± 0.21, P < 0.05). In addition, an increased utilization rate of all monoamines was found in the amygdala after ayahuasca administration in doses: 250 mg/kg (noradrenaline: 0.16 ± 0.02 vs 0.36 ± 0.06, P < 0.01; dopamine: 0.39 ± 0.012 vs 2.39 ± 0.84, P < 0.001; serotonin: 1.02 ± 0.22 vs 4.04 ± 0.91, P < 0.001), 500 mg/kg (noradrenaline: 0.08 ± 0.02 vs 0.36 ± 0.06, P < 0.001; dopamine: 0.33 ± 0.19 vs 2.39 ± 0.84, P < 0.001; serotonin: 0.59 ± 0.08 vs 4.04 ± 0.91, P < 0.001) and 800 mg/kg (noradrenaline: 0.16 ± 0.04 vs 0.36 ± 0.06, P < 0.001; dopamine: 0.84 ± 0.65 vs 2.39 ± 0.84, P < 0.05; serotonin: 0.36 ± 0.02 vs 4.04 ± 0.91, P < 0.001). CONCLUSION: Our data suggest increased release of inhibitory amino acids by the hippocampus and an increased utilization rate of monoamines by the amygdala after different doses of ayahuasca ingestion.